PHarmacist Avoidance or Reductions in Medical Costs in CRITically Ill Adults: PHARM-CRIT Study

Megan A. Rech
Loyola University

Payal K. Gurnani
Rush Medical College

William J. Peppard
Froedtert Hospital

Keaton S. Smetana
Ohio State University

Megan A. Van Berkel
Erlanger Medical Center

See next page for additional authors
Follow this and additional works at: https://uknowledge.uky.edu/pps_facpub

Part of the Pharmacy and Pharmaceutical Sciences Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Repository Citation
Rech, Megan A.; Gurnani, Payal K.; Peppard, William J.; Smetana, Keaton S.; Van Berkel, Megan A.; Hammond, Drayton A.; and Flannery, Alexander H., "PHarmacist Avoidance or Reductions in Medical Costs in CRITically Ill Adults: PHARM-CRIT Study" (2021). Pharmacy Practice and Science Faculty Publications. 71.
https://uknowledge.uky.edu/pps_facpub/71

This Article is brought to you for free and open access by the Pharmacy Practice and Science at UKnowledge. It has been accepted for inclusion in Pharmacy Practice and Science Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
PHarmacist Avoidance or Reductions in Medical Costs in CRITically Ill Adults: PHARM-CRIT Study

Digital Object Identifier (DOI)
https://doi.org/10.1097/cce.0000000000000594

Notes/Citation Information
Published in Critical Care Explorations, v. 3, issue 12, e0594.

Copyright © 2021 The Authors

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Authors
Megan A. Rech, Payal K. Gurnani, William J. Peppard, Keaton S. Smetana, Megan A. Van Berkel, Drayton A. Hammond, and Alexander H. Flannery

This article is available at UKnowledge: https://uknowledge.uky.edu/pps_facpub/71
OBJECTIVES: To comprehensively classify interventions performed by ICU clinical pharmacists and quantify cost avoidance generated through their accepted interventions.

DESIGN: A multicenter, prospective, observational study was performed between August 2018 and January 2019.

SETTING: Community hospitals and academic medical centers in the United States.

PARTICIPANTS: ICU clinical pharmacists.

INTERVENTIONS: Recommendations classified into one of 38 intervention categories (divided into six unique sections) associated with cost avoidance.

MEASUREMENTS AND MAIN RESULTS: Two-hundred fifteen ICU pharmacists at 85 centers performed 55,926 interventions during 3,148 shifts that were accepted on 27,681 adult patient days and generated $23,404,089 of cost avoidance. The quantity of accepted interventions and cost avoidance generated in six established sections was adverse drug event prevention (5,777 interventions; $5,822,539 CA), resource utilization (12,630 interventions; $4,491,318), individualization of patient care (29,284 interventions; $9,680,036 cost avoidance), prophylaxis (1,639 interventions; $1,414,465 cost avoidance), hands-on care (1,828 interventions; $1,339,621 cost avoidance), and administrative/supportive tasks (4,768 interventions; $656,110 cost avoidance). Mean cost avoidance was $418 per intervention, $845 per patient day, and $7,435 per ICU pharmacist shift. The annualized cost avoidance from an ICU pharmacist is $1,784,302. The potential monetary cost avoidance to pharmacist salary ratio was between $3.3:1 and $9.6:1.

CONCLUSIONS: Pharmacist involvement in the care of critically ill patients results in significant avoidance of healthcare costs, particularly in the areas of individualization of patient care, adverse drug event prevention, and resource utilization. The potential monetary cost avoidance to pharmacist salary ratio employing an ICU clinical pharmacist is between $3.3:1 and $9.6:1.

KEY WORDS: cost; medical care; medication; pharmacist; safety; value

Almost 1.5 million patients were admitted to ICUs in the United States in 2015 (1). The costs associated with providing critical care services in ICUs represented approximately 1% of the U.S. gross domestic product (2). Healthcare teams in ICUs have evolved to incorporate practitioners in other professions, including pharmacists (3). Many ICU pharmacists complete specialty residency or fellowship training and are board certified in critical care. The role of pharmacists has shifted from preparing and dispensing medications to performing direct patient care as a member of multidisciplinary teams. These activities have demonstrated improved clinical and financial outcomes across various patient subpopulations and hospital structures (4–9). Consequently, many...
professional healthcare organizations consider pharmacists practicing in the ICU to be essential healthcare providers, yet the participation of pharmacists in critical care units is not universal (10–13).

Previous studies of interventions performed by ICU pharmacists have more commonly focused on adverse drug event (ADE) prevention and reductions in medication use and costs (4–6). Although two multicenter studies performed at the institution level and using insurance claims data evaluated a broader scope of clinical and economic outcomes, the pharmacists’ specific interventions and roles in patient care were unknown (7, 8).

A single contemporary study at an academic medical center evaluated a medical ICU pharmacist’s clinical activities over a 12-month period and determined the cost avoidance (CA) of those activities exceeded $3 million with a monetary benefit-to-cost ratio of 24.5:1 (9). However, these findings may not be generalizable to other ICUs and hospital settings because of the patient population, pharmacist’s training and relationships with providers, and rounding structure. The purposes of this study were to comprehensively classify interventions performed by pharmacists in the ICU and quantify CA generated through accepted interventions.

**METHODS**

**Study Design**

The PHarmacist Avoidance or Reductions in Medical costs in CRITically ill adults (PHARM-CRIT) study was a multicenter, prospective, observational study that was performed in community hospitals and academic medical centers in the United States between August 2018 and January 2019. Recruitment was performed using electronic mail. Invitations were sent to the Society of Critical Care Medicine’s (SCCM’s) Clinical Pharmacy and Pharmacology section listserv. From this listserv, which includes multiple healthcare professionals, in addition to pharmacists, clinical pharmacists who provided direct (rounding with the ICU team) or decentralized (not directly rounding with the ICU team) patient care for critically ill adults were eligible for study participation. Pharmacists completing residency or fellowship were ineligible. Only interventions made by a pharmacist for patients residing in an ICU were eligible for study inclusion. Multiple pharmacists from the same institution were eligible to participate. In order to maximize data capture for pharmacist interventions, no minimum or maximum duration of study participation by each pharmacist was required; however, participants were encouraged to document interventions for 20 shifts. All clinical interventions made by participating pharmacists during study participation were recorded in REDCap© (Version 6.18.1, 2019; Vanderbilt University, Nashville, TN) in accordance with best practices (14–16). Only interventions for adults 18 years old or older that were accepted were included in the analyses.

**Data Collection**

A comprehensive, evidence-based framework for categorizing and monetizing CA interventions by critical care and emergency medicine pharmacists including 38 unique interventions within six intervention sections was developed by our group a priori and previously published (17). These interventions included direct cost of medications (e.g., IV to oral conversions) as well as potential CA associated with initiating drug therapy (e.g., initiating venous thromboembolism prophylaxis [Supplemental Table 1, http://links.lww.com/CCX/A870]). Interventions were classified according to 38 different intervention categorizations organized into six different sections: ADE prevention, resource utilization, individualization of patient care, prophylaxis, hands-on care, and administrative and supportive tasks. Any intervention that could not be classified into one of the 38 intervention categories was not recorded or available for study inclusion. All participants received training on appropriate documentation of interventions using the CA framework. Interventions were entered at the patient level by each individual pharmacist. Pharmacists were encouraged to enter these data in real time. Although all interventions (accepted and not accepted) were captured, only interventions accepted and implemented by the medical team were included in the CA analysis. The Rush University Medical Center Institutional Review Board (IRB) served as the central and coordinating IRB (IRB number 18021508-IRB01). This study was endorsed by the SCCM’s Discovery Research Network and was a work product of SCCM’s Clinical Pharmacy and Pharmacology Section.

**Study Outcomes and Statistical Analysis**

The primary outcomes were the quantity and type of interventions provided and the potential CA generated...
from clinical pharmacists practicing in ICU settings. The values for CA overall and per patient day were calculated by summing the CA for each intervention based on values from our previously published systematic framework and expressed in 2019 U.S. dollars. (17, 18) A sensitivity analysis was conducted to evaluate CA from just those interventions with the highest quality of evidence (evidence from well-designed controlled trials with or without randomization) according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence-to-decision framework (GRADE Ia-Iib interventions) (17). These interventions included the following: 1) medication route: IV-to-oral conversion (resource utilization section), 2) medication route: hypertensive crisis management (resource utilization), 3) antimicrobial therapy initiation and streamlining (individualization of patient care), 4) change venous thromboembolism prophylaxis to most appropriate agent (prophylaxis), and 5) initiation of venous thromboembolism prophylaxis (prophylaxis) (17).

Descriptive statistics were used to characterize the data. The Shapiro-Wilks test was used to determine normality of continuous data. Normally distributed data were expressed as mean (sd); nonnormally distributed data were expressed as median (interquartile range [IQR]). The CA per pharmacist shift value was annualized using 240 shifts, which corresponds to five shifts per week for 48 weeks to allow for not providing care on personal time off and holidays. This annualized CA for a pharmacist was compared with the average pharmacist's salary and benefits ($185,470) to calculate a monetary CA to pharmacist salary ratio (18, 19). Analyses were performed in Stata (Version 16; StataCorp LLC, College Station, TX).

RESULTS

Overall, 302 pharmacists responded to our invitation to participate, of whom 215 participated in the study. These 215 pharmacists at 85 centers completed 3,148 shifts. Slightly greater than half of the participating pharmacists provided care in a medical ICU (58.6%) or surgical ICU (53.0%). More than one third of ICUs had an open practice model, and 87.4% of the ICUs had interdisciplinary patient care rounds at least 5 days per week. ICU pharmacists spent the majority of their shift providing direct patient care (median, 5.5 hr [IQR, 4–8 hr]). Approximately half of each pharmacist’s shift included prospective order verification (median, 4 hr [IQR, 0–6 hr]). ICU pharmacists most frequently rounded with a single service (62.8%) although almost one third of participants rounded with two or more services each shift. The median number of shifts for participating pharmacists was 17 (IQR, 6–20). ICU pharmacists cared for a median of 15 patients each day (IQR, 12–22). Most ICU pharmacists had been in practice for at least 1 year but less than 12 years and were board certified (Table 1).

Of the 56,866 interventions performed by ICU pharmacists, 55,926 (99.4%) were accepted. These interventions were performed on 27,681 patients in six categories: ADE prevention (accepted interventions: 5,777; percentage of total accepted interventions: 10.3%), resource utilization (12,630; 22.5%), individualization of patient care (29,284; 52.4%), prophylaxis

|TABLE 1. ICU Pharmacist Characteristics|
|---|
|Characteristics | ICU Pharmacist ($N = 215$) |
|Practice area$^a$ | |
|Decentralized | 42 (19.5) |
|Burn ICU | 19 (8.8) |
|Cardiac ICU (medical) | 79 (36.7) |
|Cardiac ICU (surgical) | 87 (40.5) |
|Immunocompromised ICU | 23 (10.7) |
|Medical ICU | 126 (58.6) |
|Mixed ICU (medical/surgical) | 60 (27.9) |
|Neuro ICU (medical/surgical) | 80 (37.2) |
|Surgical ICU | 114 (53.0) |
|Trauma ICU | 75 (34.9) |
|Open ICU practice model, $n$ (%) | 82 (38.1) |
|ICU rounding 5–7 d per week, $n$ (%) | 188 (87.4) |
|Beds in ICU practice area, median (IQR) | 22 (16–27) |
|Nonpharmacist providers in practice area$^b$ | |
|Advanced practice provider | 162 (75.3) |
|Hospitalist | 55 (25.6) |
|Intensivist | 194 (90.2) |
|Fellow | 129 (60.0) |
|Resident | 165 (76.7) |

(Continued)
TABLE 1. (Continued). ICU Pharmacist Characteristics

| Characteristics | ICU Pharmacist (N = 215) |
|-----------------|--------------------------|
| Institution type, n (%) |                          |
| Academic medical center | 38 (44.7) |
| Community teaching | 30 (35.3) |
| Community nonteaching | 16 (18.8) |
| Government | 1 (1.2) |
| Shift duration (hr), n (%) |          |
| 8 | 2,452 (77.9) |
| 10 | 552 (17.5) |
| 12 | 51 (1.6) |
| Other | 93 (3.0) |
| Shifts worked, median (IQR) | 17 (6–20) |
| Direct patient care duration per shift (hr), median (IQR) | 5.5 (4–8) |
| Prospective order verification duration per shift (hr), median (IQR) | 4 (0–6) |
| Services rounded with each day, n (%) |          |
| 0 | 231 (7.4) |
| 1 | 1,945 (62.8) |
| 2 | 653 (21.1) |
| 3 | 165 (5.3) |
| 4 or more | 105 (3.4) |
| Patients cared for per shift (n), median (IQR) | 15 (12–22) |
| Years in practice (yr), n (%) |          |
| \(\leq 1\) | 27 (12.6) |
| > 1 to 3 | 74 (34.4) |
| > 3 to 6 | 50 (23.3) |
| > 6 to 12 | 40 (18.6) |
| \(\geq 12\) | 24 (11.2) |
| Board certified, n (%) | 174 (81.0) |

IQR = interquartile range.

*Cumulative percentage exceeds 100% because many pharmacists practice in multiple areas.
*Cumulative percentage exceeds 100% because multiple providers in practice areas and many pharmacists practice in multiple practice areas.

(1,639; 2.9%), hands-on care (1,828; 3.3%), and administrative/supportive tasks (4,768; 8.5%). The most frequent interventions were discontinuation of clinically unwarranted therapy (8,842; 15.8%), renal dosage adjustments in patients not receiving continuous renal replacement therapy (CRRT) (8,557; 15.3%), initiation of nonantimicrobial therapy (7,764; 13.9%), and antimicrobial therapy initiation and streamlining (5,019; 9.0%). The least commonly accepted interventions were medication route for resolving shock management (percentage accepted: 60.5%) and prevention of unnecessary high-cost medication (93.7%). Interventions from the five most validated intervention categories used in our sensitivity analysis totaled 9,175 (16.4% of all accepted interventions) (Table 2).

The CA generated from ICU pharmacist recommendations totaled $23,404,089 in six sections: ADE prevention (CA: $5,822,539; percentage of total CA: 24.9%), resource utilization ($4,491,318; 19.2%), individualization of patient care ($9,680,036; 41.4%), prophylaxis ($1,414,465; 6.0%), hands-on care ($1,339,621; 5.7%), and administrative/supportive ($656,110; 2.8%). The areas of greatest CA were medication route for hypertensive crisis management ($3,436,598; 14.7%), major ADE prevention ($3,242,171; 13.9%), and antimicrobial therapy initiation and streamlining ($3,088,944; 13.2%). In our sensitivity analysis of interventions with the highest level of evidence, CA from the five most validated intervention categories totaled $7,961,681 (34.0% of CA from all accepted interventions) (Table 2).

When considering all accepted interventions, average CA was $418 per intervention, $845 per patient each day, and $7,435 per ICU pharmacist shift. The annualized CA from an ICU pharmacist was $1,784,302. The potential monetary CA to pharmacist salary ratio was $9.6:1. When considering accepted interventions from the five most validated intervention categories, average CA was $868 per intervention, $288 per patient each day, and $2,529 per ICU pharmacist shift. Considering these categories only, the annualized CA from an ICU pharmacist was $606,990, and the potential monetary CA to pharmacist salary ratio was $3.3:1.

DISCUSSION

This is the first multicenter prospective study to comprehensively classify interventions performed by pharmacists in adult ICUs and quantify potential CA generated through these interventions. The CA generated from 215 pharmacists practicing in the ICU over the study period totaled over 23 million U.S. dollars. This CA resulted from pharmacists intervening almost 56,000 times over...
TABLE 2.  
Accepted Pharmacist Interventions and Potential Cost Avoidance

| Intervention                                                                 | Accepted, n (%) | Cost Avoidance, $ |
|------------------------------------------------------------------------------|-----------------|-------------------|
| **Section 1: Adverse drug event prevention**                                 |                 |                   |
| Major ADE prevention                                                         | 968 (97.2)      | 3,242,171         |
| Minor ADE prevention                                                         | 1,894 (98.7)    | 772,766           |
| Medication reconciliation resulting in major ADE prevention                  | 170 (99.4)      | 569,390           |
| Medication reconciliation resulting in minor ADE prevention                  | 696 (96.8)      | 328,687           |
| Recommend laboratory monitoring                                              | 2,049 (98.3)    | 909,525           |
| **Section 2: Resource utilization**                                          |                 |                   |
| Preventing unnecessary laboratories and/or tests                             | 415 (98.3)      | 8,085             |
| Prevention of inappropriate screening of heparin induced thrombocytopenia     | 40 (97.6)       | 31,843            |
| Medication route: IV to oral conversion                                       | 2,908 (97.6)    | 159,419           |
| Medication route: hypertensive crisis management                             | 164 (97.6)      | 3,436,598         |
| Medication route: resolving shock management                                 | 23 (60.5)       | 1,716             |
| Discontinuation of clinically unwarranted therapy                            | 8,842 (98.3)    | 604,881           |
| Prevention of unnecessary high-cost medication                              | 238 (93.7)      | 248,776           |
| **Section 3: Individualization of patient care**                             | 29,284 (98.3)   | 9,680,036         |
| Dosage adjustment: continuous renal replacement therapy                      | 712 (98.5)      | 1,813,357         |
| Dosage adjustment: no continuous renal replacement therapy                   | 8,557 (98.6)    | 1,398,814         |
| Antimicrobial therapy initiation and streamlining                            | 5,019 (97.0)    | 3,088,944         |
| Anticoagulant therapy management                                             | 1,806 (98.7)    | 1,262,069         |
| Initiation of nonantimicrobial therapy                                       | 7,764 (98.2)    | 1,307,535         |
| Antimicrobial pharmacokinetic evaluation                                     | 4,398 (99.1)    | 740,667           |
| Total parenteral nutrition management                                        | 1,028 (99.1)    | 68,650            |
| **Section 4: Prophylaxis**                                                   | 1,639 (99.5)    | 1,414,465         |
| Change venous thromboembolism prophylaxis to most appropriate agent          | 329 (100)       | 27,610            |
| Initiation of venous thromboembolism prophylaxis                             | 755 (99.2)      | 1,249,110         |
| Initiation of stress ulcer prophylaxis                                       | 375 (99.5)      | 21,251            |
| Initiation of ventilator associated pneumonia prophylaxis with chlorhexidine | 180 (99.5)      | 116,494           |
| **Section 5: Hands-on care**                                                 |                 |                   |
| Bedside monitoring                                                           | 1,150 (98.5)    | 446,798           |
| Emergency code blue participation                                            | 213 (99.1)      | 327,498           |
| Rapid response team participation                                            | 82 (97.6)       | 13,810            |
| Emergency code stroke participation                                          | 43 (100)        | 29,311            |
| Emergency code sepsis participation                                          | 23 (100)        | 36,453            |
| Blood factor stewardship                                                     | 36 (100)        | 346,609           |
| Emergency procedural sedation or rapid sequence intubation participation     | 131 (99.2)      | 36,333            |
| Medication teaching or discharge education                                   | 146 (97.3)      | 100,067           |
| Culture follow-up after emergency department discharge                       | 4 (100)         | 2,742             |
| Antivenin stewardship                                                        | 0               | 0                 |

(Continued)
the course of greater than 27,000 patient days. In total, 99.4% of these interventions were accepted. ICU pharmacists generated $7,435 in CA per shift when all interventions were considered and $2,529 in CA per shift when only the most validated intervention categories were used. A significant portion of CA resulted from interventions that individualized patient care, prevented ADEs, and used resources more effectively. The potential monetary CA to pharmacist salary ratio for ICU pharmacists appears to be between $3.3:1 and $9.6:1.

Major ADE prevention provided the second largest amount of CA among the six intervention categories. The use of multiple agents with a narrow therapeutic index in critically ill patients with altered pharmacokinetics and pharmacodynamics places these patients at great risk for complications (20). The significant impact pharmacists have on ADE prevention aligns with results from a landmark trial, which described a 66% relative risk reduction in ADEs following inclusion of a clinical pharmacist (5). In addition to preventing almost 3,000 ADEs during direct and decentralized patient care activities, 866 additional ADEs were prevented as a result of interventions made following medication reconciliation. For critically ill patients, determining appropriate medication dosages, time of last dose, presence of medications that may result in withdrawal symptoms, and duplicative therapies are the most common interventions that prevent an ADE (21, 22).

Approximately one fifth of ICU pharmacist interventions supported more efficient utilization of healthcare resources. Pharmacists in the ICU commonly converted more expensive IV medications to oral dosage forms with similar efficacy or discontinue certain prophylactic medications when they are no longer indicated. These are common practices that often are performed pursuant to a protocol or collaborative practice agreement and can reduce ADEs and decrease prescription costs at hospital discharge (23, 24). Improved management of hypertensive crises was the intervention associated with the greatest CA in this study. Additionally, antimicrobial agents were frequently discontinued because their empirical use was no longer necessary or a shorter duration of use that still would adequately treat a presumed or confirmed infection was deemed appropriate (25).

 Improved management of hypertensive crises was the intervention associated with the greatest CA in this study. Additionally, antimicrobial agents were frequently discontinued because their empirical use was no longer necessary or a shorter duration of use that still would adequately treat a presumed or confirmed infection was deemed appropriate (25). Improved management of hypertensive crises was the intervention associated with the greatest CA in this study. Additionally, antimicrobial agents were frequently discontinued because their empirical use was no longer necessary or a shorter duration of use that still would adequately treat a presumed or confirmed infection was deemed appropriate (25). Finally, interventions that improved resource utilization also frequently reduced the use of medications that are on shortage in the United States. These stewardship activities are imperative and challenging in an era of medication shortages but are necessary to maintain a medication's stock for treating the most critical and compelling indications and patients (26). ICU pharmacists are well positioned to incorporate the costs and availability of medications into the clinical decision-making process and patient care (27).

Individualizing therapies for specific patients was the most common classification of intervention performed by ICU pharmacists, representing 52.4% of all included interventions. These interventions represented approximately 41% of the CA generated from ICU pharmacist recommendations. The pharmacists’ ability to individualize antimicrobial dosing initially and in response to pharmacokinetic and pharmacodynamic monitoring variables in

![Table 2](image-url)
patients with renal dysfunction, especially those receiving CRRT, significantly impact patient care (28). Additionally, ICU pharmacists were active in determining the most appropriate empirical antimicrobial therapies and de-escalating to definitive therapy or discontinuing treatment in these complex patients. Pharmacists are best positioned to ensure patient care is individualized with regard to the “five rights” of medication use: the right patient, the right drug, the right time, the right dose, and the right route (29).

A pharmacist intervention to ensure prophylaxis was provided for patients at risk for preventable complications of critical illness was performed infrequently, totaling less than 3% of interventions and approximately 6% of CA. Although these interventions are not often viewed as highly impactful, they do result in a reduced rate of complications in high-risk patients and are processes that can be protocolized at many institutions (23, 24). ICU pharmacists also were involved in the infrequent but highly complex activities that represent hands-on care, which accounted for approximately 3% of interventions and almost 6% of CA. They commonly participated in emergency code blue (i.e., cardiac arrest) response, which has been shown to improve compliance with advanced cardiac life support guidelines (30, 31). Additionally, ICU pharmacists were active in acute stroke management, which frequently reduces door-to-needle times and increases the proportion of patients who are eligible to receive thrombolytics (32, 33). Finally, blood factor stewardship represented a significant portion of CA for this category of intervention. In these activities, pharmacists ensure appropriate use of blood factor products and dosages is achieved (34, 35). In critical and emergent situations, pharmacists bring expertise that complement other team members and elevate the clinical and safety outcomes for patients (36).

Fundamentally, our analysis provides estimates of CA, but such estimates are sensitive to underlying assumptions. We used an evidence-based framework for the types of interventions and associated CA from published literature to classify interventions and quantify their CA; however, these CA values are imperfect and may result in both over- or underestimation of the true CA, depending on the patient, pharmacist institution, and situation (17). We used fixed costs per intervention documented, although we acknowledge that the costs may vary by center, participant, and other conditions including medication costs. Specifically for categories such as ADE avoidance, our approach assumed that pharmacist interventions consistently lead to avoidance of an adverse event that was destined to occur (i.e. 100% probability of harm), which we recognize may not always be a valid assumption and risk overinflating CA estimates given that an adverse event would not have occurred or the intervention may have ultimately been detected by another member of the healthcare team. A recent scoping review of CA from pharmacist interventions demonstrated high risk of inflation and limited assessment of probability of harm (38). We attempted to mitigate this risk with the incorporation of a sensitivity analysis using only the CA categories with the highest levels of evidence, although only five intervention categories have CA values that come from controlled studies. The results from the sensitivity analysis that used only these intervention categories was used to anchor the lowest suspected CA from ICU pharmacists. Although the rate and type of preventable ADEs were determined in a similar manner to past studies, the counterfactual or true extent of ADE development cannot be known. Participating pharmacists were encouraged to err on the side of underemphasizing the extent of an ADE, which may have resulted in an underappreciation of the true CA from ADE prevention. In studies of this nature, the reduction in potential harm and associated CA from an intervention is difficult to precisely determine. In addition to a probabilistic factor that an identified scenario actually leads to harm, the CA of an intervention likely varies per patient, and again we used fixed estimates for these categorizations. Nevertheless, a substantial decrease in the quantity of accepted interventions or actual CA from these interventions would need to occur to cause the return on investment for ICU pharmacists demonstrated in this study to approach unacceptable values. Even for the cost estimates that were directly quantifiable such as direct pharmaceutical costs of agents, we recognize that costs may vary significantly per center. Furthermore, the evidence-based framework only included categorized interventions for which there were pre-existing data (17). Although this framework is based on published literature, it has not been prospectively validated with probabilistic CA considerations included. This also implies that if an intervention was not included as a category, we were unable to capture activities not quantified in the framework that may still generate CA for critically ill patients. Although categorizing CA in healthcare is a difficult task, particularly
in critically ill patients, proposed guidance has recently been published for CA studies in pharmacy practice, including a probabilistic framework (39).

There are several ways in which CA may be overestimated. In addition to the aforementioned challenges of fixed CA values, participants may have documented accepted interventions more frequently than accepted or inflated interventions performed, although attempts to reduce this Hawthorne effect were instituted (37). Although selection bias was mitigated by the diversity of pharmacists with regard to training, experience, and hospital, we cannot rule out the possibility that pharmacists electing to participate in the study are more likely to either make interventions and/or document those interventions compared with pharmacists not participating. Conversely, CA may have been underestimated as well through a host of factors. Additionally, the quantity and type of interventions were likely incomplete because data collection was performed in real-time. A greater quantity of interventions may have been performed than were documented. Furthermore, sustained interaction between an ICU pharmacist and healthcare team may alter the potential CA of a pharmacist over time. When first incorporating an ICU pharmacist, potential CA may be much larger as pharmacists likely have a larger impact given protocol development, education, implementation of best practice, and other initial benefits. This time-varying CA of ICU pharmacists is hypothesis generating only as we were not able to evaluate in our study. Although many ICU clinical pharmacists were included, these results may not be generalizable to all ICU pharmacists and hospitals. Additionally, there was substantial variability in the number of shifts contributed by ICU pharmacists (IQR, 6–20); it is unclear how this affected our findings. Finally, many other factors may have impacted the quantity and types of interventions as well as their acceptance, including interpersonal traits, professional relationships with other healthcare providers, and patient volume and complexity during the study period.

CONCLUSIONS

ICU pharmacists resulted in significant avoidance of healthcare costs, particularly in the areas of individualization of patient care, ADE prevention, and resource utilization. The potential monetary CA to pharmacist salary ratio for ICU pharmacists appears to be between $3.3:1 and $9.6:1.

ACKNOWLEDGMENT

We would like to thank William Adams, PhD, for his help in consultation on study design and methods.

REFERENCES

1. Emergency Department Visits. Available at: https://www.cdc.gov/nchs/fastats/emergency-department.htm. Accessed July 25, 2019
2. Halpern NA, Pastores SM: Critical care medicine in the United States 2000–2005: An analysis of bed numbers, occupancy rates, payer mix, and costs. Crit Care Med 2010; 38:65–71
3. NIH consensus development conference on critical care medicine. Crit Care Med 1983; 11:466–469
4. Montazeri M, Cook DJ: Impact of a clinical pharmacist in a multidisciplinary intensive care unit. Crit Care Med 1994; 22:1044–1048
5. Leape LL, Cullen DJ, Clapp MD, et al: Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999; 282:267–270
6. Zampieri FG, Salluh JIF, Azevedo LCP, et al; ORCHESTRA Study Investigators: ICU staffing feature phenotypes and their

www.ccejournal.org

December 2021 • Volume 3 • Number 12
relationship with patients' outcomes: An unsupervised machine learning analysis. Intensive Care Med 2019; 45:1599–1607

7. MacLaren R, Bond CA, Martin SJ, et al: Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections. Crit Care Med 2008; 36:3184–3189

8. MacLaren R, Bond CA: Effects of pharmacist participation in intensive care units on clinical and economic outcomes of critically ill patients with thromboembolic or infarction-related events. Pharmacotherapy 2009; 29:761–768

9. Hammond DA, Flowers HJC, Meena N, et al: Cost avoidance associated with clinical pharmacist presence in a medical intensive care unit. J Am Coll Clin Pharm 2019; 2:610–615

10. Rudis Ml, Brandl KM: Position paper on critical care pharmacy services. Society of Critical Care Medicine and American College of Critical Care Medicine Task Force on Critical Care Pharmacy Services. Crit Care Med 2000; 28:3746–3750

11. Lat I, Paciullo C, Daley MJ, et al: Position paper on critical care pharmacy services: 2020 update. Crit Care Med 2020; 48:e813–e834

12. Dager W, Bolesa S, Brophy G, et al: An opinion paper outlining recommendations for training, credentialing, and documenting andJustifying critical care pharmacy services. Pharmacotherapy 2011; 31:135e–175e

13. ASHP’s Section Advisory Groups (SAG) Emergency Medicine. Available at: https://www.ashp.org/pharmacy-practice/resource-centers/emergency-medicine. Accessed July 25, 2019

14. Harris PA, Taylor R, Thielke R, et al: Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377–381

15. Harris PA, Taylor R, Minor BL, et al: REDCap Consortium: The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019; 95:103208

16. Obeid JS, McGraw CA, Minor BL, et al: Procurement of shared data instruments for research electronic data capture (REDCap). J Biomed Inform 2013; 46:259–265

17. Hammond DA, Gurnani PK, Flannery AH, et al: Scoping review of interventions associated with cost avoidance able to be performed in the intensive care unit and emergency department. Pharmacotherapy 2019; 39:215–231

18. Bureau of Labor Statistics: CPI-All Urban Consumers (Current Series). Available at: https://data.bls.gov/pdq/. Accessed February 2, 2019

19. Bureau of Labor Statistics: Occupational Outlook Handbook (Pharmacists). Available at: https://www.bls.gov/ooh/healthcare/pharmacists.htm#tab-1. Accessed December 4, 2019

20. Blix HS, Viktil KK, Moger TA, et al: Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients. Pharm Pract (Granada) 2010; 8:50–55

21. Institute for Healthcare Improvement: How-to Guide: Prevent Adverse Drug Events by Implementing Medication Reconciliation. Cambridge, MA, Institute for Healthcare Improvement, 2011. Available at: http://www.ihi.org/resources/Pages/Tools/HowtoGuidePreventAdverseDrugEvents.aspx. Accessed February 4, 2019

22. Tully AP, Hammond DA, Li C, et al: Evaluation of medication errors at the transition of care from an ICU to mon-ICU location. Crit Care Med 2019; 47:543–549

23. Buckley MS, Park AS, Anderson CS, et al: Impact of a clinical pharmacist stress ulcer prophylaxis management program on inappropriate use in hospitalized patients. Am J Med 2015; 128:905–913

24. Hammond DA, Killingsworth CA, Painter JT, et al: Impact of targeted educational interventions on appropriateness of stress ulcer prophylaxis in critically ill adults. Pharm Pract (Granada) 2017; 15:948

25. Shah NH, Do LV, Petrovich J, et al: Reducing cost and intravenous duration of nicardipine in intracerebral hemorrhage patients via an interdisciplinary approach. J Stroke Cerebrovasc Dis 2016; 25:2290–2294

26. Spellberg B, Rice LB: Duration of antibiotic therapy: Shorter is better. Ann Intern Med 2019; 171(3):210–211

27. Mazer-Amirshahi M, Goyal M, Umar SA, et al: U.S. drug shortages for medications used in adult critical care (2001-2016). J Crit Care 2017; 41:283–288

28. Hammond DA, Chiu T, Painter JT, et al: Nonpharmacist health care providers' knowledge of and opinions regarding medication costs in critically ill patients. Hosp Pharm 2018; 53:188–193

29. Rhodes A, Evans LE, Alhazzani W, et al: Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017; 45:486–552

30. Grissinger M. The five rights. P T 2010; 35:542.

31. Draper HM, Eppert JA: Association of pharmacist presence on compliance with advanced cardiac life support guidelines during in-hospital cardiac arrest. Ann Pharmacother 2008; 42:469–474

32. McAllister MW, Chestnutt JG: Improved outcomes and cost savings associated with pharmacist presence in the emergency department. Hosp Pharm 2017; 52:433–437

33. Rech MA, Bennett S, Donahy E: Pharmacist participation in acute ischemic stroke decreases door-to-needle time to recombinant tissue plasminogen activator. Ann Pharmacother 2017; 51:1084–1089

34. Montgomery K, Hall AB: Impact of an emergency medicine pharmacist on time to thrombolysis in acute ischemic stroke: Strength of association. Am J Emerg Med 2017; 35:345

35. Trueg AO, Lowe C, Kiel PJ: Clinical outcomes of a pharmacy-led blood factor stewardship program. Am J Ther 2017; 24:e643–e647

36. Rech MA, Adams W, Smetana KS, et al: PHarmacist Avoidance or Reductions in Medical Costs in Patients Presenting the Emergency Department: PHARM-EM study. Crit Care Explor 2021; 3:e0406

37. Sedgwick P, Greenwood N: Understanding the Hawthorne effect. BMJ 2015; 351:h4672

38. Narayan SW, Abraham I, Erstad BL, et al: Methods used to attribute costs avoided from pharmacist interventions in acute care: A scoping review. Am J Health Syst Pharm 2021; 78:1576–1590

39. Patanwala AE, Narayan SW, Haas CE, et al: Proposed guidance on cost-avoidance studies in pharmacy practice. Am J Health Syst Pharm 2021; 78:1559–1567